FDA
-
-
-
-
-
-
-
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
-
-
-
-
-
-
-
Syndax Announces Participation in Upcoming Investor Conferences
-
-
-
-
-
-
-
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
-
-
-
-
-
-
-
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
-
-
-
-
-
-
-
Syndax Pharmaceuticals' (SNDX) Revuforj Expansion a Long-term Growth Lever- Stifel
-
-
-
-
-
-
-
Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

